Akeagen’s proprietary CaMouseTM/CanAbsTM platform (patent pending) combines the full diversity of mouse immune system with powerful antibody engineering technologies to generate monoclonal single domain antibody-based drug candidates against novel and complex targets with great efficacy.
Properties of CanAbsTM monoclonal single domain antibodies:
• High affinity, stability and specificity due to in vivo maturation
• useful for challenging targets
• Unique binding capacity to hidden epitopes (small cavities or clefts)
• single domain offering fast-track lead optimization
• Easy to engineer bi-specific and tri-specific antibodies
• Highly stable under extreme temperature and pH
• Enhanced tissue penetration, cross blood-brain-barrier
• Humanization much easier than conventional monoclonal antibodies
• Cost-effective large-scale production
AKEAGEN INC
Free Support
+1.9498386753
AKEAGEN INC © ALL RIGHTS RESERVED.
Company